Found 1256 clinical trials
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
TREATMENT OF LIVER FIBROSIS IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
NASH IS LIVER INFLAMMATION AND DAMAGE CAUSED BY A BUILDUP OF FAT IN THE LIVER.
- 93 views
- 03 Oct, 2019
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Cardiology/Vascular Diseases
-
Currently Recruiting
A research study for patients with cystic fibrosis who might have a condition called Fibrosing Colonopathy (FC).
A research study for patients with cystic fibrosis who might have a condition called Fibrosing Colonopathy (FC).
- 574 views
- 07 Nov, 2020
- 1 location

NASH001 - Non-alcoholic Steatohepatitis (NASH) - CC-90001-NASH-001 - US
and 400 mg PO QD), compared with placebo, in NASH subjects with Stage 3 and Stage 4 fibrosis.This study is designed to assess response to treatment on measures of fibrosis and other efficacy
- 85 views
- 05 Jan, 2021
- 37 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
The AURORA Study
Assessing the efficacy and safety of Cenicriviroc for the treatment of liver fibrosis in adults with non-alcoholic steatohepatitis (NASH)
- 295 views
- 23 Nov, 2020
- 1 location
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
NASH (Nonalcoholic Steatohepatitis)
Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. ClinSearch is enrolling volunteers with a condition called liver fibrosis from NASH
- 35 views
- 23 Nov, 2020
- 1 location
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy (MARVEN Study)
Implantable cardioverter defibrillator (ICD) for primary prevention of mortality is an approved therapy in ischemic and nonischemic cardiomyopathy patients with left ventricular ejection fraction (EF) ≤35%. However, data from clinical trials leading to this indication in nonischemic cardiomyopathy (NICM) patients were limited. The DEFINITE [1] trial (458 patients; hazard ratio …
- 350 views
- 24 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
Currently Recruiting
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
- 2074 views
- 08 Nov, 2020
- 1 location
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Rare Diseases and Disorders
-
Currently Recruiting
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that becomes worse over time. There is currently no effective treatment for it. Researchers
- 162 views
- 23 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
Currently Recruiting
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)
- 210 views
- 23 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
Gastroenterology
-
Currently Recruiting
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS
The study aims to evaluate The effect of oral (PO) CC-90001, administered once daily (QD), compared with placebo, will be evaluated in subjects with NASH and Stage 3 fibrosis
- 58 views
- 23 Nov, 2020
- 1 location